Short-term space travel causes many of the same molecular and physiologic changes as long-term space missions, but most reverse within months of returning to Earth. Yet, those changes that are longer-lasting and distinct between crew members reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX and other organizations.
, the WorldQuant Professor of Genomics and Computational Biomedicine at Weill Cornell Medicine, led the Space Omics and Medical Atlas (SOMA) project with Afshin Beheshti of the Broad Institute and NASA. In total, more than 100 investigators from institutions in more than two dozen countries contributed to the project. Together, the collaborators increased the amount of human spaceflight data by tenfold, including analyses of changes in gene expression, gene regulation, protein production, metabolism and the microbes in the human body. The results were published on June 11 as a 40-article collection in Nature journals and summarized in an overview article.
The SOMA team, including co-corresponding author, , an assistant professor of computational biology research in medicine at Weill Cornell Medicine, also has compiled more than 75 billion genetic sequences in an interactive atlas accessible to other researchers, and Weill Cornell Medicine will host a for nearly 3,000 biological samples from the studies. Mason’s team has already begun collecting samples from other missions and forged several new international collaborations to harmonize efforts for spaceflight research.
“This is the largest treasure trove of data from astronauts and space biology ever released,” said Mason, who is also a professor of physiology and biophysics, a professor of neuroscience in the Feil Family Brain and Mind Research Institute, member of the Sandra and Edward Meyer Cancer Center, and director of the WorldQuant Initiative for Quantitative Prediction. “We hope that sharing the data will help accelerate discoveries on the health impacts of space flight and yield fundamental discoveries on human health overall.”
Commercial astronauts
When the Inspiration4 mission launched on Sept. 16, 2021, with the first all-civilian, four-person crew for a three-day flight to low-Earth orbit, it provided an unprecedented opportunity for science. Before the mission, most data on the health impacts of space travel had been collected by government-sponsored space agencies from carefully selected and highly trained astronauts, but it was unclear if such data collected from the astronauts would apply more widely to the public; the Inspiration4 mission provided an opportunity to find out.
Mason served as the principal investigator for the Inspiration4 mission’s work on clinical profiles of the crew, multi-omics research and biobanking. Crewmembers collected biological samples before, during and after the flight and gave researchers full access to study and share their data. They also conducted a battery of experiments midflight, including the first-ever direct RNA sequencing and biopsied skin from astronauts. Drs. , , and at Weill Cornell Medicine, and , associate professor in the Meinig School of Biomedical Engineering in Cornell Engineering, also contributed to the project.
The new data was compared with that collected from previous flights, in particular, the NASA Twins Study, for which Mason was also a principal investigator. That endeavor analyzed data from astronaut Scott Kelly during and after his one-year mission on the International Space Station in 2015-16 and found that longer space flights contribute to significant changes in gene expression in the blood, particularly in the immune system and DNA repair systems. New data from Jiwoon Park showed these differences also appeared in the skin.
The Inspiration4 data showed that many of the same changes also occurred in short-term space travelers. For example, Mason published a study with showing that the telomeres, which cap the ends of chromosomes, began lengthening even during the 3-day Inspiration4 mission. They also saw similar immune system changes, with a spike in anti-inflammatory proteins called cytokines in the astronauts after their return to gravity.
Immune system alterations
The cytokine spike after reentry was one of several immune system changes documented by Weill Cornell Medicine investigators. Single-cell genetic sequencing, led by JangKeun Kim and Braden Tierney, research associates in the Mason lab, helped the scientists identify immune cells called CD16 monocytes as the cells most responsive to the stresses of spaceflight. These immune first responders undergo dramatic changes in gene expression and changes in chromatin that regulate gene expression.
“The immune system is primed for a fight, but it doesn’t yet know what it is fighting,” Mason said. He noted that the space travelers’ exposure to low-dose radiation may trigger this immune response, as well as the telomere changes.
While some parts of the immune system ramp up, others ramp down. For example, travelers experience reduced expression of genes that encode immune system proteins called human leukocyte antigens, which help the body identify viruses and other invaders. This discovery may explain why about half of space travelers and astronauts experienced reactivation of old viral infections like the herpes simplex virus-1, a primarily benign virus that causes cold sores.
Another study, led by Nadia Houerbi and Irina Matei, a graduate student in the Mason lab and postdoctoral fellow in the Lyden lab, respectively, found evidence of brain proteins in the blood of the Inspiration4 space travelers as well as the blood of six Japanese astronauts and Scott Kelly. The discovery suggests some disruption in the blood-brain barrier, which protects the brain from invasion by immune cells. Samples from mouse studies from Xiao (Vivian) Mao at Loma Linda University confirmed that spaceflight perturbed the blood-brain barrier function.
“It is nothing worrisome, but it was surprising, and worth keeping an eye on in future missions,” Mason said.
Though the Inspiration4 crew experienced many of the same changes as longer-term space travelers, they recovered quickly after the flight. Mason noted that within six months, the crew’s biology had returned to its preflight state for more than 95% of the proteins, chromatin states and genes, including RNA modifications measured by Kirill Grigorev and Theodore Nelson, researchers in the Mason Lab.
‘Second Space Age’ and Aerospace Medicine Biobank
The findings provide much fodder for future studies. Despite having data on a small number of space travelers, the SOMA researchers detected a few differences in men and women, leveraging data from at University of Maryland. For example, female space travelers return to their preflight states more quickly after returning to Earth, yet some cytokines stayed elevated in the women longer than men and were confirmed across 64 other astronauts. Individuals’ physiologic responses to space travel also varied, and genes related to drug processing (called pharmacogenomics) were also distinct.
“We might have to personalize medications and other countermeasures for different crew members based on their individual responses to space flight,” said lead and co-corresponding author of the SOMA study overview , a research associate in Mason’s lab during the study who is now starting her own lab on Bioastronautics at the University of Austin.
Making the atlas and biobank accessible to more scientists may help accelerate the pace of discovery on the impacts of spaceflight and its parallels with aging, chronic diseases and immune system disorders, according to Overbey. She noted that space travel mimics some of the effects of aging, such as bone and muscle loss, and may provide a way to test medications to counteract these changes.
“Opening up the data to the whole scientific community increases our ability to make connections between space-related changes and human health more generally,” she said.
Overbey also suggested that the growing number of commercial spaceflights and crews may help expand the dataset and increase its power to detect smaller differences.
“We are entering a new space age,” Mason said. “We have more data and more space launches than ever before, and we will need all possible biomedical data to make precision medicine for future crews a reality and to prepare for longer missions to the Moon and Mars.”
Participating institutions included the Japanese Aerospace Exploration Agency (JAXA); the European Space Agency; the ³Ô¹ÏÍøÕ¾ Aeronautics and Space Administration (NASA); and SpaceX, a company offering commercial spaceflight missions.
The research reported in this story was supported in part by NASA and the ³Ô¹ÏÍøÕ¾ Cancer Institute and the ³Ô¹ÏÍøÕ¾ Institute of Mental Health, both part of the ³Ô¹ÏÍøÕ¾ Institutes of Health. Additional support was provided by Sovaris Aerospace and WorldQuant.
Dr. Mason is an unpaid member of the board of directors for BioAstra; he holds equity/stock in Cosmica Inc.; he is a paid consultant for Thorne Research; and he has served as a speaker-lecturer for WorldQuant LLC.
Bridget Kuehn is a freelance writer for Weill Cornell Medicine.
